

Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ

Ref: FOI-032026-0002278

Date: 27.03.2026

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000.

Please provide the following information relating specifically to the use of Kenalog (triamcinolone) within your Ophthalmology department:

Please provide the following information relating specifically to the use of Kenalog (triamcinolone) within your Ophthalmology department:

1. The number of Kenalog administrations carried out in Ophthalmology for each of the last three financial years. – **63**
2. A breakdown of the clinical indications recorded for Kenalog use in Ophthalmology (e.g., uveitis, macular oedema, post-operative inflammation), if available. – **Unable to run a report for this information**
3. Any local guidelines, protocols, or clinical policies governing the use of Kenalog in Ophthalmology. – **Patients with Pseudophakic Cystoid Macular, Macular Telangiectasia (Mac Tel II) and Intraocular Inflammation that do not respond to medical management are treated with Intravitreal injection of Intracinol (Ophthalmic licensed Triamcinolone).**

The injection can be repeated (if necessary). The patient is to be given an information leaflet on 'Intravitreal Triamcinolone Acetonide (intracinol) injection', containing further relevant information which includes, benefits, risks, other possible limitations and alternatives.

Please also see the attached document and the patient information leaflet

4. Any recorded adverse events, Datix reports, or safety concerns relating to Kenalog use in Ophthalmology during the same period. - **None**
5. The number of vials issued by pharmacy to Ophthalmology for Kenalog in each of the last three financial years, if held.

22-23: 0 vials

23-24: 9 vials

24-25: 10 vials

25-26: Full Financial Year of data not yet available

6. Whether Kenalog (triamcinolone) is listed on the Trust's formulary for Ophthalmology, and if so, any restrictions or criteria for its use.

- Kenalog (triamcinolone) for ophthalmology is not listed on the Formulary.

7. As Kenalog has been withdrawn from the UK market, please provide any recorded information, internal communications, policies, or decisions relating to:

- whether the Ophthalmology department is continuing to use existing stock - **not applicable as not on formulary and not using**
- any plans or decisions to discontinue its use, and - **not applicable as not on formulary and not using**
- any identified or recommended alternative treatments - **not applicable as not on formulary and not using**

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

**Freedom of Information Team
The Dudley Group NHS Foundation Trust**